Oncofetal antigen/immature laminin receptor antibodies for diagnostic and clinical applications
AssigneeQuantum Immunologics, Inc.
InventorEric W. Olle
Life of this patent
Estimating the term…
Abstract
The present invention relates to antibodies against Oncofetal Antigen/immature Laminin receptor protein (OFA/iLRP) that can be used singly or in conjunction to detect or treat OFA/iLRP-related diseases. More specifically, the antibodies can be used for several purposes including: (i) detecting and measuring OFA/iLRP in different biofluids; and (ii) using OFA/iLRP with an antibody directed against the monomeric form and its associated diseases.
Claims24
An isolated antibody that specifically binds to a region of the oncofetal antigen/immature laminin receptor protein (OFA/iLRP), wherein the region is immunogenic.
A method of detecting OFA/iLRP in a sample comprising:
- (a) contacting the sample with a first and a second antibody that specifically bind to a region of OFA/iLRP, wherein at least one of the antibodies is specific for OFA/iLRP;
- (b) allowing the antibodies to bind to OFA/iLRP and form a sandwich with OFA/iLRP;
- and
- (c) detecting the expression of OFA/iLR in the sample using the antibody specific for OFA/iLRP.
A method of detecting cancer in a sample comprising:
- (a) contacting the sample with antibodies specific for OFA/iLRP;
- (b) contacting the sample with a biotinylated secondary antibody;
- and
- (c) detecting OFA/iLRP in the sample using streptavidin,
- wherein the detection of OFA/iLRP in the sample is indicative of cancer.
A method of determining the amount of OFA/iLRP in a sample comprising:
- (a) conjugating an antibody specific for OFA/iLRP to a fluorophore;
- (b) contacting the conjugated antibody with sample;
- and
- (c) determining the amount of OFA/iLRP in the sample using fluorescent polarization.
A method of determining the amount of OFA/iLRP positive cancer cells in a blood sample comprising:
- (a) contacting a blood sample with an antibody specific for OFA/iLRP and
- (b) determining the amount of OFA/iLRP in the sample using flow cytometry.
A method of treating a OFA/iLRP positive cancer comprising administering an amount of antibodies specific for OFA/iLRP to a subject with the OFA/iLRP positive cancer that are in an amount sufficient to treat the cancer.
A method of detecting a OFA/iLRP positive cancer in a subject comprising:
- (a) conjugating antibodies specific for OFA/iLRP to a radio opaque dye;
- (b) administering the conjugated antibody to a subject;
- and
- (c) detecting the conjugated antibody using an x-ray,
- wherein the detection of OFA/iLRP on the x-ray is indicative of cancer.
Dependencies are inferred from the claim text.